In relapsed chemotherapy-sensitive disease, ASTCT—using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology—strongly recommend an autoSCT for all nodal PTCL subtypes including ALK-positive ALCL if not done as upfront consolidation or an alloSCT if an autoSCT was performed in the frontline setting. Here, ALK is linked to mature T-cell and NK-cell non-Hodgkin lymphoma.